{"filings":[{"id":91071,"accession_number":"0001104659-26-056316","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q3 FY2026: Sales $383.5M (+10%), Adj. EBITDA $60.8M (+11%); Guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $383.5M, +10% YoY; Animal Health segment +13% to $291.2M, driven by MFA portfolio, nutritional specialties, vaccines.","Net income $24.0M, +15%; diluted EPS $0.59; adjusted diluted EPS $0.76, +19% YoY.","Updated FY2026 guidance: net sales $1.46B-$1.50B (14% growth), adjusted EBITDA $247M-$255M (37% growth).","Post-quarter: expanded revolver by $125M to $435M; announced Sustainable Solutions Platform with VERRATAIN; Brazil regulatory development on antimicrobials noted.","Gross margin improved 270 bps to 32.8%; free cash flow $12.8M trailing twelve months; leverage 3.1x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1121346000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91070,"accession_number":"0001104659-26-055699","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12/share quarterly dividend, payable June 24, 2026","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on June 24, 2026, to stockholders of record at close of business on June 3, 2026.","Dividend amount unchanged from prior quarter; no change in rate disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91069,"accession_number":"0001104659-26-052956","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Phibro Animal Health expands revolving credit facility by $125M to $435M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolver increased from $310M to $435M via Amendment No. 1 dated April 28, 2026.","New lenders include Bank of America, Citibank, BMO, Compeer Financial, and others.","Upfront fee of 0.15% of new commitments paid to incremental lenders.","Proceeds available for general corporate purposes under the existing credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91068,"accession_number":"0001104659-26-049485","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Brazilian MAPA bans Phibro's virginiamycin and bacitracin growth promoters; 180-day transition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MAPA Ordinance 1617 prohibits import, manufacture, marketing and use of antimicrobial feed additives including virginiamycin and bacitracin for growth promotion.","Transition period of 180 days from April 27, 2026; products can still be sold under current labels during that time.","Phibro expects new therapeutic registrations for virginiamycin in cattle and broilers during transition; bacitracin already has therapeutic claims.","Company expects limited impact on fiscal year 2026 results; also launching PhibroVet digital prescription platform.","Additional details to be provided on May 7, 2026 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91067,"accession_number":"0001104659-26-043188","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Joyce J. Lee resigns from Phibro Animal Health Board, effective April 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyce J. Lee, a Class II Director, informed the Company of her resignation effective April 15, 2026.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement has been announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100973,"accession_number":"0001104659-26-010345","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q2 net sales up 21% to $374M; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $373.9M (+21% YoY); net income $27.5M vs $3.2M; diluted EPS $0.67 vs $0.08.","Adjusted diluted EPS $0.87 (+58% YoY); adjusted EBITDA $68.1M (+41% YoY).","Animal Health sales +26% to $290M, driven by $57.5M incremental MFA portfolio revenue.","FY2026 guidance raised: net sales $1.45-1.50B, adjusted EBITDA $245-255M, adjusted EPS $2.93-3.10.","Gross margin improved 260 bps to 35.5%; 3.1x gross leverage ratio; free cash flow $47.3M TTM."],"consensus_eps_estimate":null,"consensus_eps_actual":1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":737803000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100972,"accession_number":"0001104659-26-009739","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable March 25","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock declared.","Payable on March 25, 2026 to stockholders of record as of March 4, 2026.","Dividend rate unchanged from previous quarter; continues regular quarterly payout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117304,"accession_number":"0001104659-25-122556","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health Announces CEO Transition: Jack Bendheim to Executive Chairman, Dani Bendheim to CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack C. Bendheim will resign as CEO and President effective July 1, 2026, and assume the new role of Executive Chairman.","Daniel (Dani) Bendheim, age 53, current EVP Corporate Strategy, will become CEO and President on July 1, 2026.","Dani Bendheim has been with Phibro since 1997 and served as VP Business Development, President Performance Products, and EVP Corporate Strategy.","Jack Bendheim, son of founder, will continue as Chairman of the Board; the Board unanimously supports the transition.","A press release announcing the leadership change was issued on December 18, 2025, and furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117303,"accession_number":"0001104659-25-107064","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Phibro Q1 net sales up 40% to $363.9M; raises FY2026 adjusted EBITDA guidance to $230-240M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $363.9M (+40% YoY); net income $26.5M ($0.65 diluted EPS) vs $7.0M ($0.17) prior year.","Adjusted diluted EPS $0.73 (doubled from $0.35); adjusted EBITDA $61.9M (+$31.2M YoY).","Animal Health sales rose 55% to $283.5M, driven by acquired MFA portfolio (+$80.5M incremental).","FY2026 guidance: Adjusted EBITDA raised to $230-240M (28% growth); net sales reaffirmed $1.43-1.48B.","Company launched Restoris™ dental gel for dogs; annual meeting reelected all director nominees and approved say-on-pay every 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":363893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117302,"accession_number":"0001104659-25-106292","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend payable Dec 17, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on December 17, 2025 to holders of record at close on November 26, 2025.","Dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133739,"accession_number":"0001558370-25-011778","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).","FY net sales $1,296.2M (+27%), adj. EBITDA $183.7M (+65%), adj. diluted EPS $2.09 (+76%).","Zoetis MFA portfolio contributed $94.5M incremental revenue in Q4 and $208.2M for full year.","FY2026 guidance: net sales $1.43-1.48B, adj. EBITDA $225-235M (25% growth), adj. EPS $2.52-2.70.","Gross leverage 3.1x as of June 30, 2025; free cash flow $41.8M for the year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1296215000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133738,"accession_number":"0001104659-25-071746","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Sept 24","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Dividend payable September 24, 2025, to holders of record at close on September 3, 2025.","Declaration by Board of Directors on July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150455,"accession_number":"0001558370-25-006760","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Q3 net sales up 32% to $347.8M; Adj EBITDA +85%; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $347.8M (+32% YoY); net income $20.9M (+$12.5M); diluted EPS $0.51 (+$0.30).","Adjusted EBITDA $54.9M (+85% YoY); adjusted diluted EPS $0.63 (+$0.32).","Animal Health segment sales +42% driven by Zoetis MFA acquisition; legacy Animal Health flat.","Updated FY2025 guidance: net sales $1.26B-$1.29B, Adj EBITDA $177M-$183M (62% growth at midpoint).","Gross leverage ratio 3.0x; free cash flow $49.1M for trailing twelve months."],"consensus_eps_estimate":0.635,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":917518000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150454,"accession_number":"0001104659-25-045063","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable June 25, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on June 25, 2025, to stockholders of record at close of business on June 4, 2025.","Dividend declared by the Board of Directors on May 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169428,"accession_number":"0001558370-25-000661","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q2 net sales up 24% to $309M; adjusted EPS $0.54 (+64% YoY); raises FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $309.3M (+24% YoY); Animal Health up 33% on Zoetis MFA acquisition added $36.7M.","Adjusted EBITDA $48.2M (+64% YoY); gross margin up 140 bps to 32.9%.","Net income $3.2M vs $1.3M prior year; adjusted net income $21.9M (+$8.5M).","Updated FY2025 guidance: net sales $1.25-1.30B, adjusted EBITDA $172-180M (58% growth midpoint).","Gross leverage 3.1x; total debt $760.3M; cash $67.1M; free cash flow $15.3M trailing 12M."],"consensus_eps_estimate":0.5304,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":569693000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169427,"accession_number":"0001104659-25-009123","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12/share quarterly dividend","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.12 per share on Class A and Class B common stock declared.","Payable March 26, 2025 to holders of record as of March 5, 2025.","No change from prior quarterly dividend rate; routine declaration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169426,"accession_number":"0001104659-25-005659","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phibro Animal Health appoints Joyce J. Lee to board as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyce J. Lee appointed as Class II independent director effective January 21, 2025, filling a vacancy.","Board expands to nine directors, six of whom are independent.","Ms. Lee most recently served as President of Cobb Vantress; prior exec roles at Elanco, Bayer Animal Health, Zoetis.","She will receive standard non-employee director compensation and has entered a director indemnification agreement.","Ms. Lee is expected to stand for election at the 2027 Annual Meeting of Stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169425,"accession_number":"0001558370-25-000053","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K/A","filed_at":"2025-01-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Phibro discloses Zoetis MFA portfolio audited financials: $407.6M revenue in FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired MFA portfolio had $407.6M revenue & $91.2M revenue less direct expenses in 2023; up from $59.9M in 2022.","Cost of sales was $284.3M in 2023 vs $310.3M in 2022; gross margin improved to 30.3% from 23.9%.","Total assets acquired as of Dec 2023: $334M; liabilities assumed: $24.5M; net assets ~$309.5M.","Transaction closed Oct 31, 2024 for $350M subject to adjustments; includes six manufacturing plants.","Pro forma financials filed for year ended June 30, 2024; combined entity impact not yet quantified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186480,"accession_number":"0001104659-24-116790","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phibro Animal Health President of North America Region retiring; Todd Armstrong promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rob Aukerman retiring as President, North America Region effective Dec 31, 2024.","Aukerman to remain in advisory capacity through June 30, 2025 for transition.","Todd Armstrong, VP of US Ruminant Business since 2020, promoted to President effective Jan 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186479,"accession_number":"0001558370-24-014663","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.","Adjusted EBITDA $30.7M, +64% YoY; adjusted diluted EPS $0.35 vs $0.14 prior year.","Updated FY2025 guidance: net sales $1.05B-$1.10B; Adjusted EBITDA $124M-$132M (15% growth).","Discontinued atopic dermatitis project; expects ~$200M sales from Zoetis MFA portfolio in FY2025.","Gross margin improved 280 bps to 32.1%; interest expense up $3.1M due to refinancing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":260432000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186478,"accession_number":"0001104659-24-114319","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable Dec 18","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on December 18, 2024; record date November 27, 2024.","Dividend rate unchanged; no increase or decrease announced.","Payment marks regular quarterly distribution to shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186477,"accession_number":"0001104659-24-113064","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.01","9.01","2.03","7.01"],"status":"ready","headline":"Phibro completes $350M acquisition of Zoetis' medicated feed additive portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired >37 product lines across ~80 countries, six manufacturing sites in US, Italy, China, and >300 employees.","Funded with $350M cash: $189M Delayed Draw Term A-1 Loans and $161M A-2 Loans under existing credit agreement.","Expected to boost profitability, EBITDA margin, and be accretive to adjusted EPS; more details on Nov 7 Q1 call.","Portfolio complements Phibro's vaccines, nutritional specialties, and mineral nutrition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203066,"accession_number":"0001558370-24-012519","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).","Full-year net sales $1,017.7M (+4%); adjusted EBITDA $111.2M (-1%); adjusted EPS $1.19 (-1%).","FY2025 guidance: net sales $1.04B-$1.09B, adjusted EBITDA $118M-$126M, adjusted EPS $1.22-$1.37.","Free cash flow $46.4M; total debt $489.1M; cash & short-term investments $114.6M; gross leverage 4.4x.","Guidance excludes proposed Zoetis MFA acquisition; company notes strength in Q4 Animal Health segment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1017679000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203065,"accession_number":"0001104659-24-083979","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12/share quarterly dividend payable Sept 25, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock declared.","Dividend payable on September 25, 2024, to stockholders of record on September 4, 2024.","Dividend amount unchanged from prior quarter; no special or increased dividend announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203064,"accession_number":"0001104659-24-078557","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Phibro Animal Health enters $960M credit facility with Rabobank; delayed draw for Zoetis acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term A-1 loans total $351M (initial $162M + delayed $189M); Term A-2 loans total $299M.","Revolving credit commitment of $310M; Term A-1 and Revolver mature July 2029, Term A-2 July 2031.","Proceeds used to refinance existing debt, pay fees, and fund Zoetis Acquisition via delayed draw facilities.","Interest rates based on Net Leverage Ratio; commitment fees 0.20%-0.35% on undrawn commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219347,"accession_number":"0001558370-24-007371","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.","Adjusted EBITDA increased 9% to $29.7M; adjusted diluted EPS rose to $0.31 from $0.29.","Affirmed FY2024 net sales guidance of $980M-$1.02B and Adjusted EBITDA of $106M-$112M.","Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio to enhance product offerings.","Vaccine sales surged 26% and MFA and other sales increased 16% in the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":744515000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219346,"accession_number":"0001104659-24-058026","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend payable June 26, 2024","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $0.12 per share on Class A and Class B common stock declared.","Payable on June 26, 2024; record date is June 5, 2024.","Press release issued May 7, 2024 via Business Wire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219345,"accession_number":"0001104659-24-053265","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health acquires Zoetis' medicated feed additive portfolio for $350M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$350M cash purchase; acquired portfolio generated ~$400M revenue in 2023 across 37 product lines.","Six manufacturing sites (four US, one Italy, one China) and >300 Zoetis employees expected to transition.","Deal expected to close H2 2024; Phibro to fund primarily with debt, targeting net leverage 3.5-4.0x at close.","Phibro expects acquisition to boost EBITDA margin and be accretive to adjusted EPS.","Combined pro forma sales ~$1.4B in last twelve months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239177,"accession_number":"0001558370-24-000864","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.","GAAP net income $1.3M, diluted EPS $0.03, down from $7.2M and $0.18 a year ago.","Adjusted EBITDA $29.5M (-5% YoY); adjusted diluted EPS $0.33 (-2%).","FY2024 guidance: reaffirmed adjusted EBITDA $106-$112M; GAAP net income lowered to $12-$17M (down 55%).","Includes $4.2M Brazil employment tax litigation charge and $7.5M foreign currency losses from Argentina devaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":481292000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239176,"accession_number":"0001104659-24-011120","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phibro Animal Health declares $0.12 quarterly dividend, payable March 27","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.12 per share on Class A and Class B common stock.","Payable on March 27, 2024 to stockholders of record on March 6, 2024.","Dividend declared by Board of Directors on February 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239175,"accession_number":"0001104659-24-010954","cik":1069899,"company_name":"PHIBRO ANIMAL HEALTH CORP","ticker":"PAHC","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Phibro Animal Health appoints Glenn C. David as CFO effective Feb 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn C. David, former Zoetis CFO and group president, joins Phibro as CFO starting Feb 9, 2024.","David receives $650K base salary, 50% target bonus, $135K signing bonus, and 300K RSUs (half time-vesting, half performance-vesting).","Performance RSUs vest based on 90-day average stock price from $20 to $60+ over 5 years.","Interim CFO Richard Johnson will stay in advisory role for smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1334173512.286817,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}